A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial.

"Conflict of Interest Statement Masatoshi Kudo: lecture: Eli Lilly, Bayer, Eisai, Chugai, Takeda, and AstraZeneca; grants: Gilead Sciences, Taiho, Otsuka, EA Pharma, AbbVie, Eisai, Chugai, and GE Healthcare; and advisory consulting: Chugai, Roche, AstraZeneca, and Eisai. Masatoshi Kudo is the Editor-in-Chief of Liver Cancer. Kazuomi Ueshima: consulting or advisory roles for Eisai, Lilly Japan, Pfizer, Chugai Pharma, and Takeda and honoraria from Bayer, Eisai, Lilly Japan, Chugai Pharma, Takeda, MSD, EA Pharma, Sumitomo Group, Taiho Pharmaceutical, and Kowa. Issei Saeki: honoraria from Eisai and research funding from Chugai Pharma. Toru Ishikawa, Nobukazu Tanabe, Yoshiyuki Wada, Masahiro Tsuda, Kazuhiko Nakao, Shunsuke Nojiri, Junji Furuse, Keisuke Hino, Chikara Ogawa, and Kenichi Yoshimura: no conflict of interest. Yoshitaka Inaba: Eisai, AstraZeneca, and Chugai. Naoki Morimoto: research funding from Eisai and AbbVie and honoraria from Eisai, AbbVie, and Chugai Pharma. Hiroshi Aikata: honoraria from Eisai and research funding from Eisai. Yasuteru Kondo: consulting or advisory roles for Terumo, Toray Medical, Hanaco Medical, UTM, Japan Lifeline, Century Medical, and Covidien. Takanori Ito: honoraria (speaker fee) from Chugai. Tetsuya Hosaka: honoraria from Gilead Sciences. Yusuke Kawamura: honoraria from Eisai, Chugai Pharma, and Terumo. Teiji Kuzuya: honoraria from Eisai, Takeda Yakuhin, Eli Lilly Japan, and Chugai Pharmaceutical. Hironori Koga: speaker honoraria from Eisai and Chugai Pharma and research grants from Shionogi, Daiichi Sankyo, and Chugai Pharma. Masafumi Ikeda: consulting or advisory roles for Eisai, Novartis, Chugai Pharma, Ono Pharmaceutical, AstraZeneca, Servier, and Takeda and honoraria from Taiho Pharmaceutical, Eisai, Lilly Japan, Chugai Pharma, AstraZeneca, and Servier. Michihisa Moriguchi: consulting or advisory roles for Bayer Yakuhin, Chugai Pharma, Eisai, and Lilly Japan and honoraria from Bayer Yakuhin, Chugai Pharma, Eisai, Lilly Japan, Takeda, and MSD. Takashi Hisai: employee of Eisai Co., Ltd. Yasuaki Arai: royalties from Sumitomo Bakelite and honoraria from Merit Medical Systems, Canon Medical Systems, Terumo International Systems, Sumitomo Bakelite, Boston Scientific, Japan Lifeline, Taiho Pharmaceutical, Guerbet Japan, AstraZeneca plc, Cosmotec, and Toray."

"This study was funded by Eisai Co. Ltd., Tokyo, Japan."